. At Yale School of Medicine, Herbst also holds the positions of associate professor of medicine (medical oncology), assistant dean for translational research, and professor of pharmacology.
“ADAURA used osimertinib in the setting of lung cancer where patients already had surgery, and the results are impressive,” said Herbst, chief of medical oncology at Yale Cancer Center. “We’re moving this effective drug therapy into the earliest stages of the disease.”
Advertisement
The randomized, double-blind, international Phase III trial evaluated the safety and efficacy of osimertinib in patients with surgically excised EGFR-mutated NSCLC who had undergone prior adjuvant chemotherapy treatment or not (1✔ ✔Trusted Source
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Go to source
According to trial findings, osimertinib significantly improved central nervous system
Osimertinib can Decrease the Risk of Death by 51%
In the overall population of patients with stage IB to IIIA disease, the ADAURA study found that osimertinib reduced the risk of death by 51%. In all, 88% of patients treated with osimertinib following surgery survived at least five years, compared to 78% of patients treated with a placebo.
“In the U.S., 10 to 15% of patients with lung cancer will have mutations in the epidermal growth factor receptor, and these patients, even after they receive the best available therapy, their tumor still often comes back,” said Herbst. “We’re now adding osimertinib, a pill that targets this specific receptor, and what we’ve found is a significant overall survival benefit for patients who received osimertinib.”
Reference :
- Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC – (https:pubmed.ncbi.nlm.nih.gov/37272535/)
Source: Medindia
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
